Similar studies for GEO DataSets (Select 200087186) - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Format

Summary
Summary (text)
Unique Identifier List

Sort by

Default order
Number of Samples (High to Low)
Number of Samples (Low to High)

Send to:

Choose Destination

File
Clipboard
Collections

Links from GEO DataSets

Items: 3

Select item 2000871861.

Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial

(Submitter supplied) We report a first-in-human trial evaluating safety and immunogenicity of a recombinant BCG, AERAS-422, over-expressing TB antigens Ag85A, Ag85B, and Rv3407 and expressing mutant perfringolysin. Interpretation: The unexpected development of VZV in two of eight healthy adult vaccine recipients resulted in discontinuation of AERAS-422 vaccine development. Immunological and transcriptomal data identified correlations with the development of TB immunity and VZV that require further investigation.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL11154
119 Samples

Download data: TXT

Series

Accession:: GSE87186

ID:: 200087186

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 2000866272.

Safety and immunogenicity of the recombinant BCG vaccine VPM1002, in South African infants

(Submitter supplied) Differential gene expression in human whole blood before and at 5 different timepoints following vaccination with BCG or VPM1002

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL21272
119 Samples

Download data: TXT

Series

Accession:: GSE86627

ID:: 200086627

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2001024593.

Adjuvant associated peripheral-blood mRNA profiles and kinetics induced by the adjuvanted recombinant-protein candidate tuberculosis vaccine M72/AS01 in BCG-vaccinated adults

(Submitter supplied) Systems biology has the potential to identify gene signatures associated with vaccine immunogenicity or protective efficacy. The main objective of our study was to identify optimal post-vaccination time points for evaluating blood RNA-expression profiles in recipients of the candidate tuberculosis vaccine M72/AS01. In this phase II open-label study (NCT01669096), healthy Bacillus Calmette-Guérin (BCG)-primed, HIV-negative adults were administered two doses (30-days apart) of M72/AS01. more...